和譽(02256.HK)已收到默克就匹米替尼全球商業化行權費8,500萬美元
和譽-B(02256.HK)公佈,其附屬和譽醫藥目前已收到默克(MRK.US)根據授權協議支付的匹米替尼(ABSK021)全球商業化選擇權行權費8,500萬美元。該選擇權行權費將確認爲2025年度公司實現的營收。
匹米替尼近期已被國家藥監局藥品審評中心納入優先審評,用於需要系統性治療的腱鞘鉅細胞瘤(TGCT)患者。同時,匹米替尼已被國家藥監局、美國食品藥品監督管理局(FDA)授予突破性療法認定(BTD),並被歐洲藥品管理局(EMA)授予優先藥物(PRIME)認定,用於治療不可手術的TGCT患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.